Literature DB >> 16999702

Quantification of tricuspid regurgitation by live three-dimensional transthoracic echocardiographic measurements of vena contracta area.

Dasan E Velayudhan1, Todd M Brown, Navin C Nanda, Vinod Patel, Andrew P Miller, Farhat Mehmood, Sanjay Rajdev, Ligang Fang, Ebenezer E Frans, Srinivas Vengala, Pavan Madadi, Pridhvi Yelamanchili, Oben Baysan.   

Abstract

We evaluated tricuspid regurgitation (TR) by multiple echocardiographic techniques in 93 consecutive patients who underwent standard two-dimensional (2D) and live three-dimensional (3D) transthoracic echocardiography (TTE). TR vena contracta (VC) area was obtained by 3D TTE by systematic and sequential cropping of the acquired 3D TTE dataset. Assessment of VC area by 3D TTE was compared to 2D TTE measurements of the ratio of TR regurgitant jet area to right atrial area (RJA/RAA), RJA alone, VC width, and calculated VC area. VC area from 3D TTE closely correlated with RJA/RAA and RJA alone as determined from 2D TTE measurements. Live 3D TTE color Doppler measurements of VC area can be used for quantitative assessment of TR and offer incremental value for quantification of particularly severe regurgitant lesions.

Entities:  

Mesh:

Year:  2006        PMID: 16999702     DOI: 10.1111/j.1540-8175.2006.00314.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  12 in total

Review 1.  Evaluation of tricuspid valve morphology and function by transthoracic three-dimensional echocardiography.

Authors:  Denisa Muraru; Luigi P Badano; Cristiano Sarais; Elena Soldà; Sabino Iliceto
Journal:  Curr Cardiol Rep       Date:  2011-06       Impact factor: 2.931

Review 2.  Echocardiographic assessment and clinical management of tricuspid regurgitation.

Authors:  Nicole M Bhave; R Parker Ward
Journal:  Curr Cardiol Rep       Date:  2011-06       Impact factor: 2.931

3.  Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design.

Authors:  Rebecca T Hahn
Journal:  Ann Cardiothorac Surg       Date:  2017-05

Review 4.  Three-Dimensional Echocardiography for Tricuspid Valve Assessment.

Authors:  Claudia Escabia; Antoni Bayes-Genis; Victoria Delgado
Journal:  Curr Cardiol Rep       Date:  2022-09-01       Impact factor: 3.955

5.  Usefulness of the multiplanar reformatting mode of three-dimensional echocardiography in evaluating valvular and structural heart disease: An experience from Saudi Arabia.

Authors:  Saad Q Khoshhal
Journal:  J Saudi Heart Assoc       Date:  2013-11-13

6.  Three-dimensional color Doppler echocardiography for direct measurement of vena contracta area in mitral regurgitation: in vitro validation and clinical experience.

Authors:  Stephen H Little; Bahar Pirat; Rahul Kumar; Stephen R Igo; Marti McCulloch; Craig J Hartley; Jiaqiong Xu; William A Zoghbi
Journal:  JACC Cardiovasc Imaging       Date:  2008-11-18

Review 7.  Feasibility and effectiveness of three-dimensional echocardiography in diagnosing congenital heart diseases.

Authors:  Saad Khoshhal
Journal:  Pediatr Cardiol       Date:  2013-05-16       Impact factor: 1.655

8.  Real-Time 3-Dimensional Echocardiographic Assessment of Effective Regurgitant Orifice Area in Dogs With Myxomatous Mitral Valve Disease.

Authors:  A Tidholm; A Bodegård-Westling; K Höglund; J Häggström; I Ljungvall
Journal:  J Vet Intern Med       Date:  2017-01-21       Impact factor: 3.333

Review 9.  Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention.

Authors:  Bushra S Rana; Shaun Robinson; Rajeevan Francis; Mark Toshner; Martin J Swaans; Sharad Agarwal; Ravi de Silva; Amer A Rana; Petros Nihoyannopoulos
Journal:  Echo Res Pract       Date:  2019-03-01

Review 10.  The tricuspid valve in review: anatomy, pathophysiology and echocardiographic assessment with focus on functional tricuspid regurgitation.

Authors:  Evin Yucel; Philippe B Bertrand; Jessica L Churchill; Mayooran Namasivayam
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.